Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GADinLADA 3-year follow-up
2023-509021-53-00Phase 2Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Jun 2024
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Diamyd in latent autoimmune diabetes in adults (LADA), sponsored by Norwegian University of Science and Technology. Primary endpoint: Change in diabetes status variables 3 years after treatment. Started Jun 2024; status: completed.
02
Drugs
Diamyd
03
Conditions
latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on 2023-509021-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509021-53-00.